The half-life of the main drugs used in clinical practice to treat advanced thyroid cancer and the half-maximal inhibitory concentration (IC50) of these drugs against the most common tyrosine kinase receptors. This evidence concerns the gene NTRK1 and thyroid gland carcinoma.